Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06341660
Status:
RECRUITING
Last Update Posted:
2024-04-02
First Post:
2024-03-13
Brief Title:
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer NSCLC
Sponsor:
Guangzhou Institute of Respiratory Disease
Organization:
Guangzhou Institute of Respiratory Disease
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-25
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-07
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-13
First Submit QC Date:
March 26 2024
Study First Post Date:
2024-04-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-26
Last Update Post Date:
2024-04-02
Last Update Post Date Type:
ACTUAL